Edwards Lifesciences Corporation

Edwards Lifesciences Corporation

EWNYSEHealthcare
$86.6
down -1.5 (-1.70%)

1-Year Price

+13.48% past year
Edwards Lifesciences Corporation (EW) 1-year price chart: up 13.48% from $76.31 on Oct 2025 to $86.60 on Oct 2026. Closing range $72.65 to $95.18.

EquityGlimpse Score

Overall
5.3/10
Wide Moat

Strong, durable competitive advantages versus peers.

Growth
2

Valuation, profitability, financial health, dividend and sentiment scores for Edwards Lifesciences Corporation (EW) are available to EquityGlimpse members.

Market Cap
49.92B
P/E Ratio
46.33
EPS
$1.84
52W High
$96.29
52W Low
$74.43
Volume
4.01M
Beta
0.86
Dividend Yield
—
Fair value estimate: sign up to see
Is EW over- or undervalued? Run DCF and multiples models on EquityGlimpse.
See fair value

Key Financial Metrics

Price to Sales
8.22
Price to Book
4.82
EV/EBITDA
33.31
Free CF per Share
$2.28
Op. CF per Share
$2.73
Debt to Equity
0.07
Gross Margin
78.13%
Net Margin
17.69%

About Edwards Lifesciences Corporation

Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascending aorta replacements, and the HARPOON Beating Heart Mitral Valve Repair System for patients suffering from degenerative mitral regurgitation. In the realm of critical care, Edwards supplies advanced hemodynamic monitoring systems that assess patients' cardiac function and fluid status in both surgical and intensive care environments. This offering also features the Acumen Hypotension Prediction Index software, which provides early alerts to clinicians regarding potential dangerously low blood pressure. The company distributes its products to healthcare providers through a combination of its proprietary sales force and independent distributor networks. Founded in 1958, Edwards Lifesciences Corporation maintains its headquarters in Irvine, California.

CEO
Bernard J. Zovighian
Industry
Medical - Devices
Employees
16,000
IPO Date
2000-03-27
Country
US
Unlock Full Analysis

Get the complete picture on Edwards Lifesciences Corporation

Sign up for EquityGlimpse to access deep fundamental data, AI reports, valuation models, and real-time tracking for EW and 8,500+ other stocks.

30 Years of Financials
Income statements, balance sheets, and cash flows with 70+ interactive charts
AI-Powered Analysis
Generate professional research reports with 15+ AI models
DCF Valuation
Run discounted cash flow models with customizable assumptions
Portfolio Tracking
Track real-time P&L, sector allocation, and dividend projections
Earnings Intelligence
Surprise tracking, revision momentum, and whisper estimates
Insider & Congress Trades
Monitor what insiders and Congress members are buying and selling

Starting at $8.25/month. 7-day free trial. Cancel anytime.